Differentiated thyroid carcinoma is thought to be a TSH-dependent tumor. TSH suppression therapy is to avoid recurrence of a differentiated carcinoma by administering an adequate dose of thyroid hormone as postoperative endocrine therapy and suppressing the secretion of TSH from the pituitary gland through its negative feedback. This CQ assessed whether this improves the prognosis.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Miyakawa M (2007) (Text in Japanese) Nihon Rinsho 65:2073–2077 (NR)Google Scholar
McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554–564 (SR<RCT>)PubMedCrossRefGoogle Scholar
Hovens GC, Stokkel MP, Kievit J (2007) Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610–2615 (RS)PubMedCrossRefGoogle Scholar
Cooper DS, Bonny S, Ho M et al (1998) Thyrotropin suppression and disease progression patients with differentiated thyroid cancer: results from the national thyroid cancer treatment cooperative registry. Thyroid 8:737–744 (PS)PubMedCrossRefGoogle Scholar
Biondi B, Filwtti S, Schlumgerger M (2005) Thyroid─hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract 1:32–40 (NR)CrossRefGoogle Scholar
Cooper DS, Doherty GM, Haugen BR et al (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142 (Others)PubMedCrossRefGoogle Scholar